Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

OncoTargets and Therapy, Aug 2017

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma Weifeng Liu,1–3,* Jie Hu,1,2,* Kaiqian Zhou,1,2,* Feiyu Chen,1,2 Zheng Wang,1,2 Boyi Liao,1,2 Zhi Dai,1,2 Ya Cao,4 Jia Fan,1,2,5 Jian Zhou1,2,5,6 1Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; 2Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai, China; 3Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 4Cancer Research Institute, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China; 5Institute of Biomedical Sciences, Fudan University, Shanghai, China; 6Shanghai Key Laboratory of Organ Transplantation, Shanghai, China *These authors contributed equally to this work Abstract: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive biomarker for many tumors. This study aimed to investigate the potential of circulating miR-125b as a prognostic marker of HCC. Exosomes were extracted from serum samples collected from two independent cohorts: cohort 1: HCC (n=30), chronic hepatitis B (CHB, n=30), liver cirrhosis (LC, n=30); cohort 2: HCC (n=128). We found that miR-125b levels were remarkably increased in exosomes compared to those in serum from patients with CHB, LC, and HCC (P

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://www.dovepress.com/getfile.php?fileID=37740

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

OncoTargets and Therapy serum exosomal mir-125b is a novel prognostic marker for hepatocellular carcinoma Kaiqian Zhou 1 2 Zheng Wang 1 2 Zhi Dai 1 2 n Zhou 1 2 3 4 0 Department of h epatobiliary and Pancreatic s urgery, the s econd a ffiliated h ospital, Zhejiang University school of Medicine , hangzhou, china 1 Key l aboratory of carcinogenesis and cancer invasion, Fudan University , Ministry of education, shanghai, china 2 liver cancer institute, Zhongshan hospital, Fudan University , shanghai, china 3 s hanghai Key l aboratory of Organ Transplantation , shanghai, china 4 institute of Biomedical sciences, Fudan University , shanghai, china 5 c ancer r esearch institute, c entral s outh University, Key l aboratory of carcinogenesis and cancer invasion, Ministry of education , changsha, china Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive biomarker for many tumors. This study aimed to investigate the potential of circulating miR-125b as a prognostic marker of HCC. Exosomes were extracted from serum samples collected from two independent cohorts: cohort 1: HCC (n=30), chronic hepatitis B (CHB, n=30), liver cirrhosis (LC, n=30); cohort 2: HCC (n=128). We found that miR-125b levels were remarkably increased in exosomes compared to those in serum from patients with CHB, LC, and HCC (P,0.01, respectively). However, miR-125b levels in exosomes and the serum from HCC patients were inferior to that of CHB (P,0.01 and P=0.06) and LC patients (P,0.01 for all). Additionally, miR-125b levels in exosomes were associated with tumor number (P=0.02), encapsulation (P,0.01), and TNM stage (P,0.01). Kaplan-Meier analysis indicated that HCC patients with lower exosomal miR-125b levels showed reduced time to recurrence (TTR) (P,0.01) and overall survival (OS) (P,0.01). Furthermore, multivariate analysis revealed that miR-125b level in exosomes, but not in serum, was an independent predictive factor for TTR (P,0.001) and OS (P=0.011). Exosomal miR-125b levels predicted the recurrence and survival of HCC patients with an area under the ROC curve of 0.739 (83.0% sensitivity and 67.9% specificity) and 0.702 (82.5% sensitivity and 53.4% specificity). In conclusion, exosomal miR-125b could serve as a promising prognostic marker for HCC. exosome; miR-125b; hepatocellular carcinoma; prognosis; serum - open access to scientific and medical research O r i g i n a l r e s e a r c h Weifeng liu 1–3,* Jie hu 1,2,* Introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer mortality globally.1 Hepatic resection and orthotopic liver transplantation is still the most effective treatment for HCC. However, the efficacy of current therapeutic regimens is poor due to the high frequency of recurrence and metastasis of HCC.2,3 Therefore, the identification of specific and sensitive biomarkers for the recurrence and prognosis of HCC is urgently needed. miRNAs are crucially implicated in a diverse range of human diseases, including cancer.4,5 Accumulating evidence indicates that dysregulation of miRNAs, especially within natural carriers and exosomes, contributes to the onset and progression of various human tumors such as breast and liver cancer.6–9 Exosomes are small membrane vesicles (40–120 nm) which play key roles in intercellular communication via delivery of active biological molecules.10,11 Extracellular miRNAs in exosomes are relatively stable and shielded against extracellular RNase degradation.12–14 Therefore, exosomal miRNAs may serve as noninvasive biomarkers for the diagnosis and prognosis of various malignancies.8,12,15 8 1 0 2 l u J 2 1 n o 7 0 2 . 6 4 . 9 5 . 7 3 y b / m o c . s s re . Previous studies reported that miR-125b was downregulated in HCC tissue, and plasma miR-125b may be a diagnostic marker for HCC.5,16–20 However, the potential significance of circulating exosomal miR-125b in HCC has not been explored. In this study, we aimed to determine whether the detection of exosomal miR-125b in HCC patients will provide information for predicting the recurrence and prognosis of HCC. Materials and methods Patients and samples Clinical samples were collected from two independent cohorts of patients recruited from Zhongshan Hospital, Fudan University (Shanghai, China) between January and June 2012. Cohort 1 comprised 30 patients with HCC, 30 with chronic hepatitis B (CHB), and 30 with liver cirrhosis (LC); cohort 2 comprised 128 patients with HCC. HCC patients in both cohorts had undergone curative resection and were histologically diagnosed. Clinical samples were collected rom oF f d e d a o l n w o d y p a r e h T d n a s t e g r a T o c n O .vdoep lsyeon fsrtoumdyaallnpdartthiecipinafnotrsmafetdercoobntsaeinnitnwgainsfoarpmpreodvceodnbseyntE. tThhiciss w u /ww lan /: o tsp rse th rp Committee of Zhongshan Hospital, Fudan University. The clinical characte (...truncated)


This is a preview of a remote PDF: https://www.dovepress.com/getfile.php?fileID=37740

Weifeng Liu, Jie Hu, Kaiqian Zhou, Feiyu Chen, Zheng Wang, Boyi Liao, Zhi Dai, Ya Cao, Jia Fan, Jian Zhou. Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma, OncoTargets and Therapy, 2017, pp. 3843-3851, DOI: 10.2147/OTT.S140062